Tag Archives: #DuchenneMuscularDystrophy

CRISPR Could Correct Majority of Duchenne Muscular Dystrophy Mutations

© 2018, GENASSIST, Inc.           

By Keith S. Wexler, MBA, CFO, Business Development Director, GENASSIST, Inc.

Paul Wexler, M.D., F.A.C.O.G., Medical Director, GENASSIST, Inc.

Clinical Professor, Department of OB/GYN, University of Colorado Health Sciences Center

Clinical Professor, Division of Genetics/Dept. of Pediatrics, Univ. of Colorado/The Children’s Hospital

https://www.genengnews.com/gen-news-highlights/crispr-technique-could-correct-majority-of-thousands-of-dmd-mutations/81255465

Background: We saw a couple that wanted to have a Level II ultrasound and possible amniocentesis due to a family history Duchenne Muscular Dystrophy (DMD). The patient and maternal grandmother’s carrier X for Duchenne Muscular Dystrophy (DMD) had been identified.

Duchenne Muscular Dystrophy (DMD) is an X-linked disease (50% of males will be affected and 50% of females will be carriers).

Rarely carrier females may manifest symptoms of the disorder but symptoms are usually milder.

Level II ultrasound was performed and the probable sex of the baby on ultrasound was male. Since the couple was concerned about the 50% risk of having a male with Duchenne Muscular Dystrophy (DMD) amniocentesis was performed.

  • The amniocentesis returned as 46,XY normal male fetus and the Duchenne Muscular Dystrophy (DMD) gene testing for the Dystrophin gene was negative.

The couple’s second pregnancy was a probable female at time of Level II ultrasound. They were not concerned about the female carrier risk of for Duchenne Muscular Dystrophy (DMD). At the time of ultrasound three ultrasound markers for a chromosomal abnormality were identified. The couple elected to have an amniocentesis to rule-out a chromosomal abnormality.

  • The amniocentesis results returned as 47,XX,+18 – Trisomy 18 female.

The couple was very disappointed to learn that their little girl was diagnosed with a probable fatal chromosomal abnormality.

Three years later the couple was pregnant again and wanted to have a Level II ultrasound to again determine sex. At time of Level II ultrasound the probable sex of the baby was male. Again since the couple was concerned about the 50% risk of having a male with Duchenne Muscular Dystrophy (DMD), amniocentesis was performed.

  • The amniocentesis returned as 46,XY normal male fetus and the Duchenne Muscular Dystrophy (DMD) gene testing for the Dystrophin gene was negative.

The couple continues to speak with us annually still perplexed by the dilemma of statistical probability, since the wife was a known carrier of Duchenne Muscular Dystrophy (DMD) and each male had a 50% risk of being affected.

They are still confused why both their males were normal and their one female turned out to have a chromosomal abnormality.

Analysis: The Dilemma of Statistical Probability is a problem that is constantly faced by healthcare providers regardless of the disease or defect the patient is concerned about.

We have pointed out to families for years that the statistical risk of having a miscarriage following an amniocentesis or having a child with Duchenne Muscular Dystrophy or some other disorder is either 0% or 100% for that patient.

Muscular Dystrophy – Duchenne

© 2017, GENASSIST, Inc.     

By Keith S. Wexler, MBA, Maternal Fetal Medicine, Prenatal Diagnosis and Biotech/Life Science Consultant, GENASSIST, Inc.

Paul Wexler, M.D., F.A.C.O.G., Medical Director, GENASSIST, Inc.

Clinical Professor, Department of OB/GYN, University of Colorado Health Sciences Center

Clinical Professor, Division of Genetics/Dept. of Pediatrics, Univ. of Colorado/The Children’s Hospital

Background: We saw a couple that wanted to have a Level II ultrasound and possible amniocentesis due to a family history Duchenne Muscular Dystrophy (DMD). The patient and maternal grandmother’s carrier X for Duchenne Muscular Dystrophy (DMD) had been identified.

Duchenne Muscular Dystrophy (DMD) is an X-linked disease (50% of males will be affected and 50% of females will be carriers).

Rarely carrier females may manifest symptoms of the disorder but symptoms are usually milder.

Level II ultrasound was performed and the probable sex of the baby on ultrasound was male. Since the couple was concerned about the 50% risk of having a male with Duchenne Muscular Dystrophy (DMD) amniocentesis was performed.

  • The amniocentesis returned as 46,XY normal male fetus and the Duchenne Muscular Dystrophy (DMD) gene testing for the Dystrophin gene was negative.

The couple’s second pregnancy was a probable female at time of Level II ultrasound. They were not concerned about the female carrier risk of for Duchenne Muscular Dystrophy (DMD). At the time of ultrasound three ultrasound markers for a chromosomal abnormality were identified. The couple elected to have an amniocentesis to rule-out a chromosomal abnormality.

  • The amniocentesis results returned as 47,XX,+18 – Trisomy 18 female.

The couple was very disappointed to learn that their little girl was diagnosed with a probable fatal chromosomal abnormality.

Three years later the couple was pregnant again and wanted to have a Level II ultrasound to again determine sex. At time of Level II ultrasound the probable sex of the baby was male. Again since the couple was concerned about the 50% risk of having a male with Duchenne Muscular Dystrophy (DMD), amniocentesis was performed.

  • The amniocentesis returned as 46,XY normal male fetus and the Duchenne Muscular Dystrophy (DMD) gene testing for the Dystrophin gene was negative.

The couple continues to speak with us annually still perplexed by the dilemma of statistical probability, since the wife was a known carrier of Duchenne Muscular Dystrophy (DMD) and each male had a 50% risk of being affected.

They are still confused why both their males were normal and their one female turned out to have a chromosomal abnormality.

Analysis: The Dilemma of Statistical Probability is a problem that is constantly faced by healthcare providers regardless of the disease or defect the patient is concerned about.

We have pointed out to families for years that the statistical risk of having a miscarriage following an amniocentesis or having a child with Duchenne Muscular Dystrophy or some other disorder is either 0% or 100% for that patient.

I had the pleasure to hear Pat Furlong, Founding President and CEO for the Parent Project Muscular Dystrophy http://www.parentprojectmd.org/site/PageServer?pagename=nws_index speak on August 26, 2016 at the Colorado Life Science Innovation Forum sponsored by the Colorado BioScience Association http://www.cobioscience.com/about-us as a panelist for “The Impact of Patient Input on R&D”.  

Pat has dedicated her life to helping end Muscular Dystrophy as well as finding treatment and cures for other rare genetic diseases: http://www.newyorker.com/magazine/2010/12/20/mother-courage-john-colapinto

*Recently a clinical trial on the effects of an investigational drug for boys ages 6-9 years with Duchenne Muscular Dystrophy was begun (DMD Myostatin Trial – call center 1-877-763-0415). We are all hoping for positive results.

Contact GENASSIST™

Fill out my online form.